Clinical Cancer Drugs - Volume 5, Issue 2, 2018

Colorectal cancer (CRC) is the 3rd most common cause of cancer death worldwide. Regular screening of the asymptomatic population can drastically reduce the mortality rate. CRC screening includes several proceedings although the gold standard remains optical colonoscopy (OC), which is unpleasant, causes pain and discomfort. New technologies exemplified by capsule endoscopy (CE) constitute alternative painles Read More

Background: Endocrine Therapy (ET) is a mainstay in Hormone Receptor-positive Breast Cancer treatment. The ability to counter estrogenic signaling in mammary tissue has made Selective Estrogen Receptor Modulators, Aromatase Inhibitors and the Selective Estrogen Receptor Degrader fulvestrant essential therapies in both early and late stage settings, with good safety profiles and benefit/ risk ratios. Nonethel Read More

Background: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, which is the leading cause of death worldwide with the majority of patients presenting with advanced disease at the time of diagnosis. Objective: In this review, the emergence of erlotinib as a seed for the treatment of NSCLC has been discussed and how it is gaining limelight as one of the most suitable drugs for this indication. The appr Read More

Background: Tumor Necrosis Factor (TNF) is a significant cytokine produced by activated monocytes/macrophages that exhibit selective cytotoxicity against various tumor cells. It has attracted attention as a potential antitumor agent through the regulation of cell proliferation, differentiation, and apoptosis. Need: Chemotherapeutic agents lack target specificity while TNF specifically attacks malignant cells through the Tumor Necro Read More

Objective: In the present study, the utilization of a novel biocompatible and biodegradable Methotrexate controlled release injectable formulation is established. The drug delivery vehicle used is an autogelling pH sensitive formulation, which is based on the natural biopolymer chitosan. Methods: Chitosan/glyceryl monooleate (C/GMO) solution was prepared in 0.33 M citric acid with gentle stirring. The weighed quantity of Drug and Read More

Objectives: Investigation of effects of lysozyme (glycoside hydrolase) on Ehrlich ascites carcinoma cells. Studies of influence of these effects on the physiological fate of cells. In particular investigations of possible apoptosis inducing effects of the enzyme by annexin V binding assay. Materials and Methods: Annexin V binding assay was applied for the detection of changes in plasma membrane of Ehrlich carcinoma cells as a result o Read More